comparemela.com

Latest Breaking News On - Human research ethics - Page 6 : comparemela.com

Argenica Therapeutics readies for phase 1 clinical trials of stroke drug

Argenica Therapeutics (ASX: AGN) is readying for phase 1 clinical trials of its stroke drug ARG-007, with pre-clinical study results anticipated throughout the current March quarter.

PharmAbcine to participate in J P Morgan Healthcare Conference and Biotech Showcase during J P Morgan Week 2022

Part of Chapel Hill s MLK Boulevard Closed Due to Gas Leak

Frontiers | All Plant Breeding Technologies Are Equal, but Some Are More Equal Than Others: The Case of GM and Mutagenesis

2School of Life and Environmental Sciences, University of Sydney, Sydney, NSW, Australia A pervasive opposition to genetically modified (GM) foods has developed from the notion that they pose a risk to human and environmental health. Other techniques for the genetic modification of plants, such as sexual crossing and mutagenesis breeding, have mostly remained unchallenged. This research aims to investigate public perception of plant breeding technologies. Specifically, sexual crossing, mutagenesis, transgenics (GM) and gene editing. It was expected that attitudes and intentions would be most positive and the perception of risk lowest for plant genetic modification through sexual crosses. Scores on these variables were expected to be similar between mutagenesis, GM and gene editing. It was also expected that attitudes, intentions and risk perception would change (becoming more positive) once participants learned about foods developed through these technologies. Participants reported

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.